Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Reports of explosions at Hama military airport in Syria
Shamkhani to Al Mayadeen: There is no mention of lifting sanctions in the latest US proposal, even though this issue is fundamental for Iran
Ali Shamkhani, political advisor to the Leader of the Islamic Revolution and the Islamic Republic of Iran, to Al Mayadeen: After receiving the American proposal, we are now preparing our new proposal
Shamkhani to Al Mayadeen: Iran will never give up its inherent rights
Iranian Defense Minister to Al Mayadeen: Israeli threats to Iran are just pointless nonsense
Iranian Defense Minister to Al Mayadeen: Those who actually possess the power and ability to threaten Iran do not speak as such; they are simply incapable of doing so
Iranian Defense Minister Aziz Nasirzadeh to Al Mayadeen: Iran possesses enough power to render 'Israel' incapable of threatening it
Hezbollah chief Sheikh Naim Qassem after meeting with Iranian FM Abbas Araghchi emphasized the importance of Iran’s positive role in the region and its support for the Palestinian Resistance and its people
Iranian FM Abbas Araghchi after meeting with Hezbollah chief Sheikh Naim Qassem: Iran is keen to assist Lebanon and stand by its side economically and politically, on the basis of mutual respect
Iranian Foreign Minister Abbas Araghchi met with Hezbollah Secretary-General Sheikh Naim Qassem, during which they discussed regional developments

Positive results, risks reported in Alzheimer's new drug

  • By Al Mayadeen English
  • Source: Agencies
  • 30 Nov 2022 12:55
3 Min Read

Full data showing that a new drug can slow cognitive decline in Alzheimer's patients was released by experts.

  • x
  • Deaths were reported at approximately the same rate in both arms of the trial of the drug, which was developed by firms Biogen and Eisai.Source:AFP
    Deaths were reported at approximately the same rate in both arms of the trial of the drug (AFP)

Experts applauded full data released on Wednesday showing that a new drug can slow cognitive decline in Alzheimer's patients but cautioned that the improvements were comparatively small and the treatment could have serious side effects.

Preliminary data from a lecanemab trial revealed that it slowed cognitive decline by 27% over an 18-month period.

The full trial data, published in the New England Journal of Medicine, expands on those findings while also raising concerns about the frequency of "adverse effects", such as brain bleeds and swelling.

According to the findings, 17.3% of patients given the drug experienced brain bleeds, compared to 9% of those having a placebo. In addition, 12.6% of those taking the drug experienced brain swelling, compared to 1.7% in the placebo group.

Read next: New Blood Test Allows for Early Detection of Alzheimer Symptoms

Deaths were reported at roughly the same rate in both arms of the drug trial, which was developed by Biogen and Eisai.

The findings were widely applauded by researchers and advocates for dementia patients, including Bart De Strooper, director of the UK Dementia Research Institute. "This is the first drug that provides a real treatment option for people with Alzheimer's," he said.

Related News

Air pollution linked to increased dementia risk: Harvard report

19-year-old Chinese man becomes youngest patient with Alzheimer's

"While the clinical benefits appear somewhat limited, it can be expected that they will become more apparent if the drug is administered over a longer time period."

Longer trials needed 

Regarding Alzheimer's disease, two key proteins, tau and amyloid beta, build up into tangles and plaques, known together as aggregates, which cause brain cells to die and lead to brain shrinkage.

Lecanemab works by targeting amyloid, and according to De Strooper, the drug not only cleared it but also had "beneficial effects on other hallmarks of Alzheimer's, including tau."

The phase three trial lasted for 18 months and involved nearly 1,800 people who were randomly assigned to either the drug or a placebo.

They were evaluated using an Alzheimer's disease clinical scale that measures cognition and function, as well as changes in amyloid levels and other indicators. However, Tara Spires-Jones, programme lead at the UK Dementia Research Institute, noted that "there is not an accepted definition of clinically meaningful effects in the cognitive test they used."

"It is not clear yet whether the modest reduction in decline will make a big difference to people living with dementia. Longer trials will be needed to be sure that the benefits of this treatment outweigh the risks," she added.

Additionally, the drug only targets those in the early stages of the disease with a certain level of amyloid buildup, limiting the number of people who could potentially benefit from the treatment. And as Alzheimer's is not always caught quickly, some experts said an overhaul in early diagnosis would be needed to ensure more people could benefit.

Previously, Biogen and Eisai put the Alzheimer's drug Aduhelm on the market, but there was significant controversy over the evidence that it worked, and its approval resulted in the resignations of three high-level FDA officials.

  • Alzheimer
  • Lecanemab
  • United Kingdom
  • Alzheimer's Disease

Most Read

Lebanon's PM Nawaf Salam meets with US envoy Morgan Ortagus in Beirut on April 5, 2025 (Dalati Nohra via AP)AP)

Morgan Ortagus to exit US role in Lebanon amid policy shift

  • Politics
  • 1 Jun 2025
Spokesperson for the Yemeni Armed Forces, Brigadier General Yahya Saree, announces a new operation against Ben Gurion Airport on May 29, 2025 (Yemeni Military Media)

Yemen announces successful hypersonic missile strike on Ben Gurion

  • Politics
  • 30 May 2025
An Israeli army vehicle moves in the Gaza Strip as seen from southern occupied Palestine, Thursday, May 29, 2025 (AP)

Hamas rejects Witkoff ceasefire plan, says alters terms

  • Politics
  • 29 May 2025
It may well be due to the longstanding relationship between MI6 and HTS, via Inter Mediate, that Britain was the first Western country to recognise their assumption of government in Syria. (Al Mayadeen English; Illustrated by Zeinab El-Hajj)

How MI6 helped HTS seize Syria

  • Opinion
  • 31 May 2025

Coverage

All
War on Gaza

Read Next

All
US-Israeli backed GHF appoints evangelical leader as new head
US & Canada

Evangelical ally of 'Israel' tapped to lead Gaza aid foundation

Ms. Rachel says she’ll risk career to support children in Gaza
Arts and Culture

Ms. Rachel says willing to risk career to support children in Gaza

A screen grab from a video showing Masked Israeli occupation forces blocked a tour with dozens of international journalists saying they’re not allowed to enter Masafer Yatta and visit Basel Adra home. (X)
Politics

'Israel' blocks media access to ‘No Other Land’ West Bank village

Supporters hold a sign before a campaign event for Donald Trump on Sept.12, 2024, in Tucson, Arizona (Alex Brandon/AP)
US & Canada

Trump’s Latino approval rating plunges, new poll reveals

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS